Stay updated on Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial page.

Latest updates to the Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page’s footer/version identifier updates from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating an internal UI release rather than a change to the recorded clinical trial information.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded Revision: v3.5.2; Deleted Revision: v3.5.0.SummaryDifference0.1%

- Check56 days agoChange DetectedNew revision entry v3.5.0 was added to the record history. Revision v3.4.3 was removed.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision: v3.4.3 was added to the history as the latest entry, replacing the previous v3.4.2.SummaryDifference0.1%

- Check84 days agoChange DetectedThe study title now specifies Etentamig (ABBV-383) for intravenous use in adults with relapsed or refractory multiple myeloma, with related sections added or updated accordingly.SummaryDifference0.6%

- Check91 days agoChange DetectedNew entry 'Revision: v3.4.2' was added to the record history. A general government operating status notice was removed from deletions.SummaryDifference0.4%

Stay in the know with updates to Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial page.